Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Chemomab (Nasdaq: CMMB) announced publication (Nov 19, 2025) of Phase 2 SPRING results for nebokitug in primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. The double-blind randomized study (n=76) evaluated IV nebokitug 10 mg/kg and 20 mg/kg vs placebo up to 15 weeks with an open-label extension to 48 weeks.
Key findings: nebokitug was generally safe and well tolerated through 48 weeks; dose-dependent biomarker improvements were observed, with the 20 mg/kg arm and patients with moderate/advanced fibrosis showing numerical and durable reductions in ELF, PRO-C3, and statistically significant reductions in liver stiffness at 15 weeks. Results support advancement to a Phase 3 registration trial.
Chemomab (Nasdaq: CMMB) announced that co-founder and CEO Adi Mor, PhD will present at Oppenheimer’s Movers in Rare Disease Summit on December 11, 2025 in New York City.
The company will deliver a corporate overview at 2:15–2:45 pm EST at the Sofitel Hotel and will be available for one‑on‑one investor meetings with registered attendees. Investors should contact their Oppenheimer representative to register and schedule meetings.
Chemomab (Nasdaq: CMMB) reported Q3 2025 results and a corporate update on Nov 20, 2025. Management said FDA and EMA provided alignment that a single nebokitug Phase 3 registration trial using a composite clinical event endpoint could support approval, and Phase 3 design is near completion.
Data from the Phase 2 SPRING open-label extension up to 48 weeks showed favorable safety and consistent improvements in inflammatory and fibrotic biomarkers. Cash, cash equivalents and short-term deposits were $10.2M as of Sept 30, 2025, funding operations through end of Q4 2026.
Chemomab (Nasdaq: CMMB) announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis (PSC) will be presented at AASLD The Liver Meeting® on November 10, 2025. Open-label extension (up to 48 weeks) data show nebokitug was well tolerated with sustained or continued improvements in inflammatory and fibrosis biomarkers, including ELF score and liver stiffness, especially at 20 mg/kg. Mechanistic analyses report dose-dependent reductions in macrophage-related proteins, a dose-dependent increase in MST1, and correlations between MST1/CCL24 changes and liver stiffness. All three posters were designated Posters of Distinction.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dr. Adi Mor will deliver a prerecorded corporate presentation, which will be available from September 5, 2025, at 7:00 am ET for 90 days via webcast. The company's management team will also conduct one-on-one investor meetings on September 8-9, 2025.
Chemomab Therapeutics (Nasdaq: CMMB) reported Q2 2025 financial results and provided updates on its lead drug candidate nebokitug for Primary Sclerosing Cholangitis (PSC). The company is preparing for Phase 3 trials while pursuing strategic partnerships to optimize development resources. Key financial metrics include cash position of $9.5 million as of June 30, 2025, with runway through Q2 2026.
Notable developments include FDA alignment on CMC standards and toxicology testing requirements, new patent issuances in China and Russia, and multiple presentations of Phase 2 SPRING trial data at major scientific meetings. The company also announced plans to implement an ADS ratio change from 1:20 to 1:80 effective August 26, 2025, essentially functioning as a 1:4 reverse split for ADS holders.
Chemomab Therapeutics (Nasdaq: CMMB) presented positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at BSG Live'25. The data was presented by Principal Investigator Dr. Douglas Thorburn at the British Society for Gastroenterology annual meeting in Glasgow.
The trial demonstrated that nebokitug was well-tolerated over 48 weeks of treatment, with a safety profile comparable to placebo during the initial 15-week double-blind portion. In patients with moderate to advanced disease, the drug showed dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects.
The open-label extension portion, lasting up to an additional 33 weeks, revealed sustained improvement in fibrosis markers and other PSC-related parameters. These positive results support advancement to Phase 3 trials, potentially positioning nebokitug as the first approved therapy for PSC.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
